Skip to main content
Type at least 3 characters

3,098 articles

Clinical Trial

Published on 14 Nov 2025

Immunogenicity and safety of an Escherichia coli-produced 9-valent human papillomavirus vaccine (types 6/11/16/18/31/33/45/52/58) in healthy Chinese women aged 20–45 years: a single-center, randomized, observer-blinded, positive controlled phase 2 clinical trial

in Vaccines and Molecular Therapeutics

  • Mingwei Wei
  • Hongyan Liu
  • Hongyang Yu
  • Hongxing Pan
  • Hong Tao
  • Jing Zhang
  • Weiwei Han
  • Dan Wu
  • Wenjuan Wang
  • Jingxin Li
Frontiers in Immunology
doi 10.3389/fimmu.2025.1706662
  • 432 views